![]() |
|
![]() |
|
Systematic (IUPAC) name | |
---|---|
(4S,6S)-2-ethylamino-4-methyl-5,5-dioxo- 5λ6,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide |
|
Identifiers | |
CAS number | 130693-82-2 120279-96-1 |
ATC code | S01EC03 |
PubChem | 3154 |
DrugBank | APRD00577 |
Chemical data | |
Formula | C10H16N2O4S3 |
Mol. mass | 324.443 g/mol |
SMILES | eMolecules & PubChem |
Pharmacokinetic data | |
Protein binding | ~33% |
Half life | 4 months |
Therapeutic considerations | |
Pregnancy cat. | ? |
Legal status |
Dorzolamide (trade name Trusopt) is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design. Dorzolamide hydrochloride is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.
The combination of dorzolamide with timolol is marketed under the trade name Cosopt.
|
|